for management of Depression, Anxiety and Insomnia



 NeuroCes™ is a battery operated portable medical device that is used for the FDA recognized treatment of anxiety, depression and insomnia via a process called Cranial Electrotherapy Stimulation (CES).

NeuroCes™ has been intended for professional and personal use. NeuroCes™ can be used in doctor’s offices, hospitals and clinics as well as at home and office without medical supervision. NeuroCes™ is safe, effective, and simple to use.

NeuroCes™ who draws advantages from the wealth of knowledge established over time has been designed to combine state-of-the-art technologies with advanced Cranial Electrotherapy Stimulation technique.


NeuroCes™ Cranial Electrotherapy Stimulator has been approved and CE certified as a therapeutic medical device for both clinical use and personal use in the treatment of Depression, Anxiety and Insomnia. NeuroCes™ reduces anxiety, depression and insomnia symptoms in a spectacular way with no significant side effects.


Five meta-analyses were computed in order to summarize most of the studies of Cranial Electrotherapy Stimulation (CES) appearing in the U.S. scientific literature. They are categorized as follows (Smith, 2007) :

Anxiety Studies

As of now, there have been at least 38 anxiety studies published, with an average 58% improvement.  The improvement found in various studies has ranged from 31% to 97%.


improvement range
31% - 97%

Depression Studies

So far, at least 18 scientific studies have been published on depression, with an average improvement of 47% reported.  The improvement found in various studies has ranged from 25% to 80%.


improvement range
25% - 80%

Insomnia Studies

So far we have more than 18 sleep studies in the scientific literature, with treated patients reporting an average of 62% improvement in sleep.  The improvement found among the various studies has ranged from 37% to 93%.


improvement range
37% - 93%

toplantı odası


NeuroCes™ is a medical device that can also be used to treat symptoms of Depression, Anxiety and Insomnia that accompany conditions such as;

  • Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder,

  • Schizophrenia Spectrum and Other Psychotic Disorders,

  • Bipolar and Related Disorders,

  • Social Anxiety Disorder (Social Phobia),

  • Panic Disorder (Panic Attack Specifier),

  • Agoraphobia,

  • Generalized Anxiety Disorder,

  • Obsessive-Compulsive and Related Disorders,

  • Trauma and Stressor Related Disorders.

For many patients suffering from depression, anxiety and insomnia who cannot achieve satisfactory results with medication or are looking for an alternative due to the side effects of medications, NeuroCes™ is an appropriate treatment option.

NeuroCes™ can also be used to help soften the initial transitory adverse effects of pharmaceuticals, such as the activation and jitteriness experienced with some of the selective serotonin reuptake inhibitors (SSRIs).


Changes in Neurochemicals​

Cerebrospinal fluid and plasma levels of five neurochemicals including serotonin, beta-endorphin, melatonin, noradrenalin and cholinesterase measured in five asymptomatic, normal subjects at rest and after 20 minutes of Cranial Electrotherapy Stimulation (CES) have been reported by Shealy, 1998.

Although cerebrospinal fluid levels of serotonin and beta-endorphin rise to a greater extent with CES, beta-endorphin, serotonin and melatonin appear to change significantly in plasma and provide observations of clinical interest. Plasma levels of noradrenalin appear to change moderately after CES. Figure 1 and Figure 2 show increased maximum level of neurochemicals in cerebrospinal and plasma in five asymptomatic, normal subjects. Hypothalamic modulation may explain the reported antidepressant effect of CES (Shealy,1989).

Figure 1. Percentage change of neurochemicals in plasma in asymptomatic, normal subjects after 20 minutes of Cranial Electrotherapy Stimulation (CES).







Figure 2. Percentage change of neurochemicals in cerebrospinal fluid in asymptomatic, normal subjects after 20 minutes of Cranial Electrotherapy Stimulation (CES).







  • Substantial increase in Serotonin, Beta Endorphins and ACTH

  • Modest increase in Cholinesterase

  • Moderate increase in Melatonin, Noradrenalin

  • Moderate decrease in Cortisol

Safety of NeuroCes™

CES has a foundation of research and clinical use from which proof of safety and effectiveness have been well established. NeuroCes™ is non-invasive and side-effects are mild and self-limiting. Significant side effects or complications attributable to the application of electric current for therapeutic effect are “virtually nonexistent”.

Effective NeuroCes™ Treatment

Following CES treatment, most patients feel less anxious, less distressed, and more focused on mental tasks. Patients with positive outcomes generally sleep better and report improved concentration, increased learning abilities, enhanced recall, and a heightened state of wellbeing after one or a series of CES treatments (Gilula, 2005).

No Placebo Effect in CES

Components of CES administration, including the level of current, pulse width, electrode placement, frequency, waveform, the number of treatments, and duration of treatment, have all been varied without causing injury or preventing positive therapeutic results. Such efficacy in the face of altering so many variables may suggest a placebo effect is responsible for benefit seen with CES; however, multiple double blind studies and animal research has shown that the placebo effect is not responsible for the benefits documented (Kennerly, 2006). No placebo effect in CES treatment has ever been found when that effect was specifically controlled for (Smith, 2007).


The CES device has been proven to inhibit, delay, and reverse the first stages of many neuropsychiatric illnesses. It is also extremely successful in preventing the exacerbation of anxiety, stress, depression, insomnia and rage. Many have found the device helpful in combating problems such as alcohol and drug addiction. It may be the most important breakthrough in electromagnetic field prophylaxis (Smith, 2007).

CE Conformity Statement

NeuroCes™ is an active medical device (Class IIa medical device in accordance with MDD Annex IX – “Classification Criteria” Rule 9) according to Medical Device Directive, which was certified according to ANNEX II (excluding Section IV) of MDD 93/42/EEC by the Notified Body, Slovenian Institute of Quality and Metrology (SIQ).


EN ISO 13485

NEUROSANTE is certified as EN ISO 13485 compliant, accredited by the Notified Body 1304, Slovenian Institute of Quality and Metrology (SIQ). EN ISO 13485 provides a great advantage for NEUROSANTE producing NeuroCes™.

The EN ISO 13485 standard governs quality management for medical devices and related services. It’s published by the International Organization for Standardization. EN ISO 13485 addresses quality control, risk management, legal compliance, operational efficiency and ability to trace and recall products and devices and process and product improvement.




NeuroCes™ reduces anxiety, depression and insomnia symptoms in a spectacular way with no significant side effects. 

Most of the users experience improvement immediately in the course of treatment

No significant side effects


Cost-effective treatment



NeuroCes™ PWL-05

Cranial  Electrotherapy Stimulator

695 €

595 €

(Smith, 2007). Ray B. Smith, Ph. D. Cranial Electrotherapy Stimulation: It’s First Fifty Years, Plus Three: A Monograph. ISBN: 978-1-60247-589-2 & Cranial Electrotherapy Stimulation Lecture.

(Shealy, 1998). Shealy, C. Norman, Cady, Roger K., Culver-Veehoff, Diane, Cox, Richard & Liss, Saul. Cerebralspinal fluid and plasma neurochemicals: response to cranial electrical stimulation. Journal of Neurological and Orthopaedic Medicine and Surgery. 18(2):94-97, 1998.

(Gilula, 2005). Marshall F. Gilula, MD, Daniel L. Kirsch, PhD. Cranial Electrotherapy Stimulation Review: A Safer Alternative to Psychopharmaceuticals in the Treatment of Depression.

(Kennerly, 2006). Kennerly, Richard C. Changes in quantitative EEG and low resolution tomography following cranial electrotherapy stimulation. August 2006, 425 pp., 81 tables, 233 figures, 171 references.